REFINE THE APPROACH
The first and only monoclonal antibody (mAb) for HAE1
TAKHZYRO provides targeted inhibition of plasma kallikrein, a critical regulator of bradykinin production, to help prevent HAE attacks.1
PATIENT TREATED WITH TAKHZYRO
HMWK=high molecular weight kininogen.
cHMWK=cleaved high molecular weight kininogen.
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Watch TAKHZYRO in action
Use this video to help explain to your patients how TAKHZYRO works in the body.
Reference: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Shire LLC; 2018.